24小时热门版块排行榜

返回列表

hdang2003

木虫 (著名写手)

应助: 1 (幼儿园)
金币: 3408.9
散金: 605
红花: 2
帖子: 1038
在线: 273.9小时
虫号: 337078
注册: 2007-04-02
性别: GG
专业: 合成药物化学

[交流] GSK中国的中药研究部门转自丁香园已有3人参与

Britain’s biggest drug maker last week unveiled the outcome of a review of its 38 groups of scientists, known as Discovery Performance Units (DPU), saying it would close three units and open four.

The Sunday Telegraph can reveal the new units will look at traditional Chinese medicines, investigating how their principles can be applied to making new, synthetic, molecules.

“Within our discovery organisation in China we have created a DPU that will marry traditional Chinese medicine with modern drug discovery and clinical efficacy,” said Moncef Slaoui, Glaxo’s chairman of research and development. “With modern technology we have the potential to yield new molecular entities with significant efficacy.”

The new unit will be based in China – Glaxo launched an R&D centre in Shanghai almost five years ago.

With its pharmaceutical market forecast to mushroom to more than $100bn (?63.5bn) by 2015, China is one of the most important battlegrounds for drug companies facing pricing pressure and more competition from generics.

Glaxo’s move reflects a wish by drug companies to adapt their research to particular regions. Six years ago, AstraZeneca established a centre in China to study diseases prevalent in Asia, such as liver and stomach cancer, and lung conditions.

Last October, Astra also said it planned to invest $200m in a new Chinese factory making intravenous and oral solid medicines.

Astra’s sales in emerging markets, including China, grew 10pc to $5.8bn last year, while Glaxo’s Asia Pacific revenues grew 7pc to ?1.8bn.

个人认为中药的前途肯定是光明的，甚至好于西药，但在过去的上千年时间里，中药的发展步伐几近停滞，是不是中药的发展得改变思路？大型药企的介入将会是个好的开端。

回复此楼